Explore the groundbreaking potential of FLASH Radiotherapy with IBA’s ConformalFLASH technology. FLASH radiotherapy delivers ultra-high radiation doses at extremely short irradiation times (≥ 40 Gy/s), significantly reducing normal tissue radiation toxicity compared to conventional therapy (0.03-1 Gy/s), with a dose-modifying factor of 1.2-1.6. This innovative approach enhances tumor control while sparing healthy tissues, offering superior efficacy in treating tumors. Preclinical studies have demonstrated the FLASH effect across various radiation types, including protons, photons, and electrons, with proton therapy showing significant normal tissue toxicity-sparing effects in both the plateau and Bragg Peak regions. IBA’s ConformalFLASH combines the physics-sparing benefits of proton therapy’s Bragg Peak with the biology-sparing benefits of ultra-high dose rate radiation. With successful demonstrations in canine models, this technology is now ready for first-in-human testing, paving the way for a new era in Radiation Oncology. Learn more about how Proton Therapy, FLASH Radiotherapy, and ConformalFLASH are revolutionizing cancer treatment.

ConformalFLASH® is the registered brand of IBA’s Proton FLASH irradiation solution, which is currently under research and development. ConformalFLASH® will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.